These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 9466490)

  • 1. Phosphatases and tumorigenesis.
    Parsons R
    Curr Opin Oncol; 1998 Jan; 10(1):88-91. PubMed ID: 9466490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer predisposition: where's the phosphate?
    Smith A; Ashworth A
    Curr Biol; 1998 Mar; 8(7):R241-3. PubMed ID: 9545192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Germline mutations in PTEN are present in Bannayan-Zonana syndrome.
    Marsh DJ; Dahia PL; Zheng Z; Liaw D; Parsons R; Gorlin RJ; Eng C
    Nat Genet; 1997 Aug; 16(4):333-4. PubMed ID: 9241266
    [No Abstract]   [Full Text] [Related]  

  • 4. Cdc25 protein phosphatases in cell proliferation.
    Draetta G; Eckstein J
    Biochim Biophys Acta; 1997 Apr; 1332(2):M53-63. PubMed ID: 9141461
    [No Abstract]   [Full Text] [Related]  

  • 5. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta.
    Li DM; Sun H
    Cancer Res; 1997 Jun; 57(11):2124-9. PubMed ID: 9187108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A study of the PTEN/MMAC1 gene in 136 breast cancer families.
    Chen J; Lindblom P; Lindblom A
    Hum Genet; 1998 Jan; 102(1):124-5. PubMed ID: 9490290
    [No Abstract]   [Full Text] [Related]  

  • 7. Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway.
    Unoki M; Nakamura Y
    Oncogene; 2001 Jul; 20(33):4457-65. PubMed ID: 11494141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Involvement of protein tyrosine phosphatases in cancer development].
    Hinoda Y; Idogawa M; Imai K
    Tanpakushitsu Kakusan Koso; 1998 Jun; 43(8 Suppl):1186-92. PubMed ID: 9655978
    [No Abstract]   [Full Text] [Related]  

  • 9. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas.
    Rhei E; Kang L; Bogomolniy F; Federici MG; Borgen PI; Boyd J
    Cancer Res; 1997 Sep; 57(17):3657-9. PubMed ID: 9288766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of CDC25A and CDC25B in head and neck cancers.
    Gasparotto D; Maestro R; Piccinin S; Vukosavljevic T; Barzan L; Sulfaro S; Boiocchi M
    Cancer Res; 1997 Jun; 57(12):2366-8. PubMed ID: 9192810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alterations of PTEN/MMAC1, a candidate tumor suppressor gene, and its homologue, PTH2, in small cell lung cancer cell lines.
    Kim SK; Su LK; Oh Y; Kemp BL; Hong WK; Mao L
    Oncogene; 1998 Jan; 16(1):89-93. PubMed ID: 9467947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The lipid phosphatase activity of PTEN is critical for its tumor supressor function.
    Myers MP; Pass I; Batty IH; Van der Kaay J; Stolarov JP; Hemmings BA; Wigler MH; Downes CP; Tonks NK
    Proc Natl Acad Sci U S A; 1998 Nov; 95(23):13513-8. PubMed ID: 9811831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma.
    Guldberg P; thor Straten P; Birck A; Ahrenkiel V; Kirkin AF; Zeuthen J
    Cancer Res; 1997 Sep; 57(17):3660-3. PubMed ID: 9288767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutational analysis of the PTEN/MMAC1 gene in non-Hodgkin's lymphoma.
    Nakahara Y; Nagai H; Kinoshita T; Uchida T; Hatano S; Murate T; Saito H
    Leukemia; 1998 Aug; 12(8):1277-80. PubMed ID: 9697884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues.
    Suzuki H; Freije D; Nusskern DR; Okami K; Cairns P; Sidransky D; Isaacs WB; Bova GS
    Cancer Res; 1998 Jan; 58(2):204-9. PubMed ID: 9443392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutation analysis of the putative tumor suppressor PTEN/MMAC1 in human ovarian cancer.
    Yokomizo A; Tindall DJ; Hartmann L; Jenkins RB; Smith DI; Liu W
    Int J Oncol; 1998 Jul; 13(1):101-5. PubMed ID: 9625810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PTEN and myotubularin: novel phosphoinositide phosphatases.
    Maehama T; Taylor GS; Dixon JE
    Annu Rev Biochem; 2001; 70():247-79. PubMed ID: 11395408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PTEN and myotubularin phosphatases: from 3-phosphoinositide dephosphorylation to disease.
    Wishart MJ; Dixon JE
    Trends Cell Biol; 2002 Dec; 12(12):579-85. PubMed ID: 12495846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A mammalian expression system for rapid production and purification of active MAP kinase phosphatases.
    Chen P; Hutter D; Liu P; Liu Y
    Protein Expr Purif; 2002 Apr; 24(3):481-8. PubMed ID: 11922765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A family of putative tumor suppressors is structurally and functionally conserved in humans and yeast.
    Li L; Ernsting BR; Wishart MJ; Lohse DL; Dixon JE
    J Biol Chem; 1997 Nov; 272(47):29403-6. PubMed ID: 9367992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.